Voss Capital LP Sells 205,000 Shares of REGENXBIO Inc. $RGNX

Voss Capital LP decreased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 41.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 295,000 shares of the biotechnology company’s stock after selling 205,000 shares during the period. Voss Capital LP owned 0.58% of REGENXBIO worth $4,248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in shares of REGENXBIO during the 3rd quarter valued at about $37,000. Jones Financial Companies Lllp boosted its holdings in REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares in the last quarter. Captrust Financial Advisors bought a new position in REGENXBIO in the second quarter worth approximately $85,000. Prudential Financial Inc. bought a new position in REGENXBIO in the second quarter worth approximately $87,000. Finally, ProShare Advisors LLC bought a new position in REGENXBIO in the fourth quarter worth approximately $155,000. Institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RGNX. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a report on Monday. Bank of America cut their price target on REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Morgan Stanley set a $16.00 price target on REGENXBIO in a report on Friday, May 15th. HC Wainwright cut their price target on REGENXBIO from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Finally, Barclays cut their price target on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, May 15th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.55.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 15,309 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $11.02, for a total value of $168,705.18. Following the transaction, the insider owned 232,617 shares in the company, valued at $2,563,439.34. This trade represents a 6.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.22% of the stock is owned by corporate insiders.

REGENXBIO Stock Up 6.1%

RGNX stock opened at $6.66 on Friday. REGENXBIO Inc. has a twelve month low of $5.45 and a twelve month high of $16.19. The stock’s 50 day moving average is $7.98 and its 200-day moving average is $10.24. The firm has a market capitalization of $344.32 million, a PE ratio of -1.19 and a beta of 1.04.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. The company had revenue of $6.39 million during the quarter, compared to the consensus estimate of $25.84 million. On average, equities research analysts anticipate that REGENXBIO Inc. will post -3.69 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.